impact of natalizumab treatment on fatigue, mood and aspects of cognition in relapsing-remitting multiple sclerosis

Clicks: 590
ID: 133721
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 263 articles by views in journal of photochemistry and photobiology a: chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 263 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background/ObjectiveFatigue, cognitive and affective disorders are relevant symptoms in Multiple Sclerosis (MS). The treatment with Natalizumab has a positive effect on physical disabilities in patients with RRMS. Some studies describe improvements in cognition and fatigue over one year of treatment. Only little is known about longer treatment effects especially on fatigue, but also on cognition and mood. Therefore the present retrospective open label observational study investigates the effect of Natalizumab on fatigue, attention and depression over a treatment period of two years. Methods 51 RRMS patients that were treated with Natalizumab (male = 11, female = 40; mean age: 33,9+9,1 years) were included. The neuropsychological assessment consisted of different tests of attention (TAP: alertness, divided attention, flexibility, SDMT, PASAT), fatigue (WEIMUS, FSMC) and depression (CES-D). The assessments occurred immediately before the first administration of Natalizumab, after one and two years of treatment. ResultsSignificant improvements were found in aspects of attention and depression from baseline to follow-up 1 (alertness: reaction time (RT) cued, p < 0.05; divided attention: visual RT, p < 0.05; SDMT: p = 0.05; CES-D: p < 0.05) and from baseline to follow-up 2 (divided attention: visual RT: p < 0.001; errors: p < 0.01, omissions: p < 0.05; flexibility: RT, p < 0.05; SDMT: p < 0.01; CES-D: p < 0.05). No significant changes were detected in fatigue probably because of the small sample size especially in the second year of treatment (WEIMUS: N = 16, FSMC: N = 8). Conclusion The results show a positive effect of Natalizumab on attention in patients with RRMS and for the first time also in depression after two years of observation and support the efficacy of the treatment over two years. More research is needed for fatigue.
Reference Key
ekunkel2015frontiersimpact Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Annett eKunkel;Martin eFischer;Judith eFaiss;Doreen eDaehne;Wolfgang eKöhler;Jürgen H. eFaiss
Journal journal of photochemistry and photobiology a: chemistry
Year 2015
DOI
10.3389/fneur.2015.00097
URL
http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00097/full
Keywords
cognition depression multiple sclerosis fatigue diseases of the nervous system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.